{"classes":[{"categories":[{"measurements":[{"comment":"Due to the low number of events, the upper CI limit was not evaluable.","groupId":"OG000","lowerLimit":"32.13","upperLimit":"NA","value":"33.97"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"}],"units":"Participants"}],"description":"PFS was defined as the time from start of treatment to the first occurrence of disease progression as assessed by the investigator according to the guidelines used at the site or death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were enrolled in an induction phase and received 6-8 cycles of obinutuzumab, combined with 6 or 8 cycles of standard chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone/methylprednisolone \\[CHOP - 21-day cycle) or bendamustine (28-day cycle), or cyclophosphamide, vincristine, and prednisone/prednisolone/methylprednisolone \\[CVP - 21-day cycle\\]). Participants received an additional two doses of obinutuzumab on Days 8 and 15 of Cycle 1. The investigator was free to choose the chemotherapy for each participant.","id":"OG000","title":"All Participants"}],"paramType":"MEDIAN","populationDescription":"The safety population included all participants who received at least one dose of obinutuzumab.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of study (up to approximately 4 years)","title":"Progression-Free Survival (PFS) Rate at the End of the Study","type":"SECONDARY","unitOfMeasure":"Months"}